Captrust Financial Advisors Has $657,000 Stock Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Captrust Financial Advisors increased its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 7.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 5,337 shares of the specialty pharmaceutical company’s stock after acquiring an additional 372 shares during the quarter. Captrust Financial Advisors’ holdings in Jazz Pharmaceuticals were worth $657,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. IFP Advisors Inc acquired a new position in shares of Jazz Pharmaceuticals in the fourth quarter worth approximately $25,000. Quadrant Capital Group LLC lifted its stake in shares of Jazz Pharmaceuticals by 97.1% in the fourth quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company’s stock worth $25,000 after acquiring an additional 101 shares during the period. CoreFirst Bank & Trust acquired a new position in shares of Jazz Pharmaceuticals in the fourth quarter worth approximately $28,000. Allianz SE acquired a new position in shares of Jazz Pharmaceuticals in the fourth quarter worth approximately $29,000. Finally, Jones Financial Companies Lllp increased its holdings in Jazz Pharmaceuticals by 75.1% in the fourth quarter. Jones Financial Companies Lllp now owns 303 shares of the specialty pharmaceutical company’s stock worth $37,000 after purchasing an additional 130 shares in the last quarter. 89.14% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, CEO Bruce C. Cozadd sold 6,500 shares of the company’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $144.25, for a total transaction of $937,625.00. Following the completion of the sale, the chief executive officer now owns 464,058 shares in the company, valued at approximately $66,940,366.50. This represents a 1.38% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Neena M. Patil sold 3,800 shares of the company’s stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $144.87, for a total value of $550,506.00. Following the sale, the executive vice president now owns 33,318 shares of the company’s stock, valued at $4,826,778.66. This trade represents a 10.24% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 28,236 shares of company stock worth $3,956,190. 4.20% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

JAZZ has been the subject of a number of research analyst reports. Wells Fargo & Company upgraded Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $130.00 to $170.00 in a report on Thursday, February 13th. Truist Financial lifted their target price on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the stock a “buy” rating in a report on Thursday, March 6th. Morgan Stanley lowered their target price on Jazz Pharmaceuticals from $183.00 to $166.00 and set an “overweight” rating for the company in a report on Wednesday, May 7th. Needham & Company LLC reiterated a “buy” rating and issued a $200.00 target price on shares of Jazz Pharmaceuticals in a report on Wednesday, May 7th. Finally, StockNews.com downgraded Jazz Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday. Two research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $182.79.

Jazz Pharmaceuticals Trading Up 2.7%

NASDAQ JAZZ opened at $108.98 on Friday. The company has a market cap of $6.72 billion, a price-to-earnings ratio of 15.35, a P/E/G ratio of 1.04 and a beta of 0.38. Jazz Pharmaceuticals plc has a 52 week low of $95.49 and a 52 week high of $148.06. The business has a 50 day moving average price of $115.73 and a 200-day moving average price of $122.01. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings data on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 EPS for the quarter, missing the consensus estimate of $4.65 by ($2.97). The firm had revenue of $897.84 million for the quarter, compared to the consensus estimate of $984.16 million. Jazz Pharmaceuticals had a net margin of 11.60% and a return on equity of 29.30%. The company’s revenue was down .5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.68 EPS. As a group, equities analysts expect that Jazz Pharmaceuticals plc will post 16.96 earnings per share for the current fiscal year.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.